相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
A. Kuendgen et al.
LEUKEMIA (2021)
Germline mutations in MDS/AML predisposition disorders
Lucy A. Godley
CURRENT OPINION IN HEMATOLOGY (2021)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
How we manage adults with myelodysplastic syndrome
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Thrombosis and platelet dysfunction in myeloproliferative neoplasms
C. Mornet et al.
REVUE DE MEDECINE INTERNE (2020)
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Eytan M. Stein et al.
LANCET HAEMATOLOGY (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients
Victoria Smith et al.
CANCER RESEARCH (2020)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner et al.
BLOOD (2020)
Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels
David H. Henry et al.
BLOOD (2020)
Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents
Anne Sophie Kubasch et al.
BLOOD (2020)
Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Michael R. Savona et al.
BLOOD (2020)
Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
David A. Sallman et al.
BLOOD (2019)
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Marie Sebert et al.
HAEMATOLOGICA (2019)
Novel therapies in low- and high-risk myelodysplastic syndrome
Ulrich Germing et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome
Wei Wang et al.
BLOOD (2019)
Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents
Bo Angela Wan et al.
BLOOD (2019)
Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
James M. Foran et al.
BLOOD (2019)
Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Sanghee Hong et al.
BLOOD (2019)
De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes
Zachary D. Epstein-Peterson et al.
BLOOD (2019)
Real-World Application of Molecular Genetic Sequencing in the Management of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: The Wisconsin Experience
Lauren Gabriele Banaszak et al.
BLOOD (2019)
Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes
Laura Roberts et al.
BLOOD (2019)
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor
Michael R. Grunwald et al.
BLOOD (2019)
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib plus Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Guillermo Garcia-Manero et al.
BLOOD (2019)
Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
Eytan M. Stein et al.
BLOOD (2019)
TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes
Christina Ganster et al.
BLOOD (2019)
Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes
Lingxu Jiang et al.
BLOOD (2019)
CPX-351 As First Intensive Therapy for Elderly Patients with AML
Ellen K. Ritchie et al.
BLOOD (2019)
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis
Pierre Fenaux et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myelodysplasies (GFM)
Thomas Cluzeau et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
Andrew H. Wei et al.
BLOOD (2019)
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Shyamala C. Navada et al.
BLOOD (2019)
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Elsa Bernard et al.
BLOOD (2019)
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Guillaume Richard-Carpentier et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan et al.
BLOOD (2019)
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
David P. Steensma et al.
BLOOD (2019)
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
Jorge E. Cortes et al.
BLOOD (2019)
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Angela Gil-Perez et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lode et al.
HAEMATOLOGICA (2018)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lode et al.
HAEMATOLOGICA (2018)
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation
Christina Rautenberg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Luis A. Carvajal et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Myelodysplastic syndromes current treatment algorithm 2018
David P. Steensma
BLOOD CANCER JOURNAL (2018)
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
Moshe Mittelman et al.
LANCET HAEMATOLOGY (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R
Christopher B. Benton et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
Hong Wang et al.
ANNALS OF HEMATOLOGY (2018)
Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy
Esther Schuler et al.
ANNALS OF HEMATOLOGY (2018)
Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome
Roman M. Shapiro et al.
CURRENT OPINION IN HEMATOLOGY (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
Aaron T. Gerds et al.
BLOOD (2018)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Guillermo Montalban-Bravo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
E. A. Eksioglu et al.
LEUKEMIA (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Gregory W. Roloff et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Uncoding the genetic heterogeneity of myelodysplastic syndrome
R. Coleman Lindsley
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Current treatment algorithm for the management of lower-risk MDS
Aristoteles Giagounidis
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
C. Scheid et al.
BONE MARROW TRANSPLANTATION (2017)
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Charles F. Craddock et al.
CLINICAL CANCER RESEARCH (2017)
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
Myelodysplastic syndromes: Contemporary review and how we treat
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Time-dependent changes in mortality and transformation risk in MDS
Michael Pfeilstoecker et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
Hereditary Predispositions to Myelodysplastic Syndrome
Sarah A. Bannon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
U. Platzbecker et al.
LEUKEMIA (2014)
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes
James M. Foran et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
Luca Malcovati et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results from an Internet-Based Survey
Mikkael A. Sekeres et al.
ONCOLOGIST (2011)
Hematopoietic Growth Factors in Myelodysplastic Syndromes
David P. Steensma
SEMINARS IN ONCOLOGY (2011)
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L. Greenberg et al.
BLOOD (2009)
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey
David P. Steensma et al.
LEUKEMIA RESEARCH (2008)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero et al.
LEUKEMIA (2008)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
LY Shih et al.
LEUKEMIA (2004)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes
AJG Jansen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
分享论文
